Whether it is new and groundbreaking research results, university topics or events – in our press releases you can find everything you need to know about the happenings at 51. To subscribe, just send an email to ott@pvw.uni-frankfurt.de
Theodor-W.-Adorno Platz 1
60323 Frankfurt
presse@uni-frankfurt.de
Prolongation of Collaborative Research Centre on selective autophagy led by 51
FRANKFURT. Four years ago, Collaborative Research Centre (CRC) 1177 on selective autophagy was established under the leadership of 51 – now the German Research Foundation has given the green light for its further funding. A total of over € 12 million has been approved for the period up until 2023. Partners alongside 51 are the universities of Mainz, Munich, Tübingen and Freiburg, the Georg Speyer Haus and the Max Planck Institute of Biophysics in Frankfurt as well as the Institute of Molecular Biology (IMB) in Mainz.
Selective autophagy is part of the cell's waste disposal system. With its help, defective or potentially damaging cellular components are degraded and recycled. It plays a central role in maintaining cellular homeostasis and fulfils important functions in ageing and developmental processes. Errors in this system contribute to cancer, neurodegenerative disorders and infections. The objective of the research alliance is a better understanding of autophagy at molecular and cellular level in order to be able in future to counteract imbalances in the system. CRC 1177 is the first consortium in Germany to tackle this important topic systematically.
“This is very good news for 51," said Professor Birgitta Wolff, President of 51. Thanks to this CRC, Frankfurt has become a national hub for autophagy research over the past four years. Especially through the integration of new partners in Munich, Tübingen and Freiburg and at the MPI for Biophysics, it has been possible to substantially strengthen the existing partnership between Mainz (IMB/JGU) and Frankfurt (GSH/GU). We expect this research alliance to advance autophagy research significantly, which will help in the fight against many diseases," said the President.
Autophagy is found from simple organisms, such as yeasts, up to humans. The underlying molecular mechanisms are always similar: Cellular components that need to be removed are recognized in a highly specific manner, enveloped by membranes and degraded. This is how, for example, aggregated proteins are destroyed that would otherwise cause severe damage and trigger cell death. This can especially be observed in neurodegenerative disorders such as Alzheimer's disease, where toxic protein aggregates accumulate which then promote the massive destruction of nerve cells. Apart from proteins, autophagy can also target defective cell organelles and pathogens for removal. The cell can reutilize the recovered material as building blocks for synthesizing new components, which is why autophagy is also an important survival strategy in times of need.
Autophagy is a very complex process which must be precisely regulated and is greatly dependent on the cellular context. Its analysis requires state-of-the-art technologies, the integration of a wide variety of data and close collaboration between researchers from different disciplines. “We will focus on novel concepts in autophagy research and its impact on major biological processes as well as pathogenesis and therapy of human diseases," explains Professor Ivan Dikic, CRC spokesperson and Director of the Institute of Biochemistry II at 51. “Our vision includes close interactions between basic and translational research via centrally supported technology platforms."
The platforms with their ultramodern equipment are a key factor in the research alliance's success: Since 2016, over 20 scientific publications have been produced in cooperation with the proteomics platform alone. In the second funding period, centrally available technologies will be significantly extended to include modelling and simulation methods, genomic and chemical high-throughput screening, and imaging methods to quantify autophagy in model organisms. Another equally important matter within the consortium is support for early career researchers. To this end, the Research Training Group set up in the first funding period will be continued. “Training the next generation of autophagy researchers is a matter close to our hearts and for this reason we've planned a diverse and advanced training programme," said Dikic.
Participating in the CRC on the part of 51 – in addition to its faculties of Biological Sciences, Biochemistry, Chemistry and Pharmacy, and Medicine – is the Buchmann Institute for Molecular Life Sciences.
Further information: Dr. Kerstin Koch, Institute of Biochemistry II, Faculty of Medicine, 51, Tel.: +49(0)69- 6301-84250, k.koch@em.uni-frankfurt.de.